ArticlePloS one2025
Longitudinal SARS-CoV-2 antibody response in a healthcare worker cohort utilising the Abbott Alinity® anti-nucleocapsid assay.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHealthcare workers (HCWs) in Ireland bore a particularly high burden of SARS-CoV-2 infections, representing over 30% of infections during initial waves. We describe the prevalence, incidence and persistence of SARS-CoV-2 anti-nucleocapsid (anti-NC) IgG positivity in a cohort of HCWs working in a Dublin inner-city tertiary hospital, over 48 weeks.
methodsThe SORTeD (Seroprevalence, Seroconversion Rates and Transmission Dynamics of SARS-CoV-2 among Healthcare Workers) study was a longitudinal cohort study of HCWs working in an inner-city hospital in Dublin between July 2020 and September 2021. Participants had either a prior history of PCR-confirmed SARS-CoV-2 (Group 1) or no prior history of SARS-CoV-2 (Group 2). Serum samples were obtained at weeks 0, 12 and 48, and tested for SARS-CoV-2 nucleocapsid (NC) antibody using a qualitative immunoassay (Abbott Alinity®). Seroprevalence rates are presented using descriptive statistics, with univariate and multivariate analysis examining associations between participant characteristics, IgG status and refractive index in Group 1. Data is presented as n (%) or median (interquartile range (IQR)) where appropriate.
resultsOf the 395 HCWs who were recruited, 304 (77.0%) were female, median age was 33 (28-45) years, and 343 (86.8%) had patient-facing roles. In Group 1, time from infection to sampling was 173 (144.0-202.0) days. Seroprevalence of IgG in Group 1 at 0, 12 and 48 weeks was 47.4%, 19.0% and 7.3%, respectively; while seroprevalence in Group 2 was 5.4%, 4.3% and 2.6%, respectively. A lower refractive index was seen in higher sampling intervals (r = -0.5, 95% CI -0.576 to -0.427; p < 0.001). Fourteen incident infections were reported by the cohort during the study, and 3 documented reinfections.
conclusionOur study shows low seroprevalence in prior confirmed cases among our HCW population, possibly explained by reduced sensitivity of this assay with increasing time from SARS-CoV-2 exposure and timing of testing. Confirmatory testing with a quantitative assay would help understand the true seroprevalence of SARS-CoV-2 IgG in this cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.